patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_392950 | REC_0015901 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 13.2 | 63 | female | 1 | 15 | 5.9 | 3 | osimertinib 80 mg daily | 6.6 | true | MSI-H | 2026-03-15T05:36:01.490347+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450160 | REC_0015902 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 10.9 | 56 | female | 1 | 15 | 7 | 3 | entrectinib 600 mg daily | 19.6 | true | MSS | 2026-03-15T05:36:01.490724+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422485 | REC_0015903 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 33 | 7.7 | 77 | female | 1 | 14 | 6.5 | 1 | entrectinib 600 mg daily | 15.9 | false | MSS | 2026-03-15T05:36:01.491096+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_513695 | REC_0015904 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 7.1 | 83 | male | 2 | 57 | 3.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.9 | false | MSS | 2026-03-15T05:36:01.491497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583420 | REC_0015905 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 20.5 | 85 | female | 2 | 0 | 6.7 | 8 | alectinib 600 mg BID | 12.8 | false | MSI-H | 2026-03-15T05:36:01.491909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200958 | REC_0015906 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 18.9 | 77 | female | 2 | 18 | 6.8 | 1 | osimertinib 80 mg daily | 31.6 | true | MSS | 2026-03-15T05:36:01.492389+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_724647 | REC_0015907 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 8.3 | 72 | male | 2 | 14 | 6 | 1 | osimertinib 80 mg daily | 26.6 | true | MSS | 2026-03-15T05:36:01.492787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756155 | REC_0015908 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 8.4 | 76 | male | 1 | 28 | 5.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:36:01.493153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703324 | REC_0015909 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 16 | 62 | female | 1 | 18 | 4.8 | 2 | sotorasib 960 mg daily | 18.1 | true | MSS | 2026-03-15T05:36:01.493535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651432 | REC_0015910 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 16 | 4.6 | 59 | female | 0 | 74 | 4.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.9 | false | MSS | 2026-03-15T05:36:01.493917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245375 | REC_0015911 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 19.8 | 64 | female | 1 | 10 | 7.2 | 8 | osimertinib 80 mg daily | 11.4 | true | MSS | 2026-03-15T05:36:01.494283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_815252 | REC_0015912 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 15.9 | 73 | male | 3 | 13 | 5 | 4 | sotorasib 960 mg daily | 8.5 | true | MSI-H | 2026-03-15T05:36:01.494691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764715 | REC_0015913 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 15.8 | 66 | male | 0 | 13 | 4.8 | 5 | pembrolizumab 200 mg q3w | 9.1 | true | MSS | 2026-03-15T05:36:01.495284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804584 | REC_0015914 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 10.9 | 82 | female | 1 | 23 | 5.4 | 5 | osimertinib 80 mg daily | 6.7 | true | MSS | 2026-03-15T05:36:01.495673+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310025 | REC_0015915 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12.2 | 58 | male | 1 | 10 | 6.8 | 8 | entrectinib 600 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:36:01.496291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_658917 | REC_0015916 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 3.5 | 59 | female | 0 | 47 | 5.8 | 1 | pembrolizumab 200 mg q3w | 10.9 | false | MSS | 2026-03-15T05:36:01.496837+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293271 | REC_0015917 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 6.4 | 66 | female | 1 | 19 | 5.5 | 4 | alectinib 600 mg BID | 12.8 | false | MSS | 2026-03-15T05:36:01.497214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546283 | REC_0015918 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 10 | 72 | female | 1 | 16 | 4.4 | 2 | sotorasib 960 mg daily | 9.7 | false | MSS | 2026-03-15T05:36:01.497628+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480381 | REC_0015919 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 8.8 | 76 | female | 1 | 19 | 4.2 | 6 | entrectinib 600 mg daily | 15 | false | MSS | 2026-03-15T05:36:01.497973+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182765 | REC_0015920 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.1 | 76 | female | 3 | 27 | 6.1 | 5 | entrectinib 600 mg daily | 8.2 | true | MSS | 2026-03-15T05:36:01.498381+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_220088 | REC_0015921 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 18.5 | 65 | male | 0 | 19 | 6.4 | 1 | alectinib 600 mg BID | 5.8 | false | MSS | 2026-03-15T05:36:01.498765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412608 | REC_0015922 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 6.3 | 69 | female | 0 | 17 | 5.9 | 6 | pembrolizumab 200 mg q3w | 5.5 | false | MSS | 2026-03-15T05:36:01.499139+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700531 | REC_0015923 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 12.7 | 62 | male | 0 | 4 | 5.6 | 2 | entrectinib 600 mg daily | 26 | true | MSS | 2026-03-15T05:36:01.499532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127297 | REC_0015924 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 10.2 | 55 | female | 0 | 7 | 4.5 | 1 | entrectinib 600 mg daily | 11.6 | false | MSI-H | 2026-03-15T05:36:01.499920+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381172 | REC_0015925 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 13.8 | 62 | male | 1 | 18 | 5.5 | 4 | osimertinib 80 mg daily | 15.2 | false | MSI-H | 2026-03-15T05:36:01.500372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_624007 | REC_0015926 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 7.3 | 79 | female | 2 | 68 | 3.8 | 0 | carboplatin + paclitaxel + pembrolizumab | 11.8 | false | MSS | 2026-03-15T05:36:01.500994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208416 | REC_0015927 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 7.4 | 65 | female | 1 | 19 | 6.3 | 8 | sotorasib 960 mg daily | 11.7 | false | MSS | 2026-03-15T05:36:01.501462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892251 | REC_0015928 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 4.8 | 57 | female | 1 | 31 | 4.2 | 7 | pembrolizumab 200 mg q3w | 4.8 | false | MSS | 2026-03-15T05:36:01.501899+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_919534 | REC_0015929 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 12.7 | 64 | female | 0 | 14 | 6.6 | 1 | pembrolizumab 200 mg q3w | 19.6 | true | MSS | 2026-03-15T05:36:01.502311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613870 | REC_0015930 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 10.7 | 58 | female | 1 | 5 | 7.3 | 7 | alectinib 600 mg BID | 15.7 | false | MSS | 2026-03-15T05:36:01.502706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437634 | REC_0015931 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 10.4 | 68 | female | 1 | 42 | 4.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.1 | true | MSI-H | 2026-03-15T05:36:01.503089+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540159 | REC_0015932 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 6.1 | 78 | female | 2 | 1 | 5 | 3 | pembrolizumab 200 mg q3w | 7.2 | true | MSS | 2026-03-15T05:36:01.503480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286449 | REC_0015933 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 8.8 | 49 | male | 0 | 14 | 6.4 | 6 | entrectinib 600 mg daily | 14.1 | false | MSS | 2026-03-15T05:36:01.503860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808844 | REC_0015934 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 4.6 | 68 | female | 1 | 50 | 4.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.6 | true | MSS | 2026-03-15T05:36:01.504304+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152712 | REC_0015935 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 4.9 | 65 | male | 1 | 2 | 4.4 | 6 | entrectinib 600 mg daily | 10.3 | true | MSS | 2026-03-15T05:36:01.504690+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976979 | REC_0015936 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 8.5 | 64 | female | 0 | 16 | 5.5 | 2 | alectinib 600 mg BID | 21.1 | true | MSS | 2026-03-15T05:36:01.505078+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108406 | REC_0015937 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 5.5 | 71 | female | 1 | 51 | 3.3 | 3 | pembrolizumab 200 mg q3w | 19 | false | MSS | 2026-03-15T05:36:01.505477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888819 | REC_0015938 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 32 | 6.6 | 67 | female | 0 | 16 | 6.1 | 1 | pembrolizumab 200 mg q3w | 22.6 | true | MSS | 2026-03-15T05:36:01.505842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680984 | REC_0015939 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 8.4 | 74 | female | 2 | 5 | 5.4 | 1 | entrectinib 600 mg daily | 14.2 | false | MSS | 2026-03-15T05:36:01.509355+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366134 | REC_0015940 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 12.6 | 59 | female | 0 | 12 | 5.9 | 7 | osimertinib 80 mg daily | 12.6 | true | MSI-H | 2026-03-15T05:36:01.509874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346382 | REC_0015941 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 14.3 | 61 | male | 1 | 16 | 6.1 | 1 | alectinib 600 mg BID | 12.7 | false | MSI-H | 2026-03-15T05:36:01.510298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569046 | REC_0015942 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 30 | 15.8 | 71 | male | 1 | 9 | 5.7 | 1 | pembrolizumab 200 mg q3w | 17.4 | false | MSI-H | 2026-03-15T05:36:01.510743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778729 | REC_0015943 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 5.1 | 69 | female | 0 | 34 | 3.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 23.9 | false | MSS | 2026-03-15T05:36:01.511136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291079 | REC_0015944 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 4.7 | 78 | male | 1 | 58 | 4.1 | 3 | carboplatin + paclitaxel + pembrolizumab | 16.9 | true | MSS | 2026-03-15T05:36:01.511523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843830 | REC_0015945 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 17 | 5.7 | 83 | male | 1 | 20 | 6.3 | 2 | sotorasib 960 mg daily | 22.3 | true | MSS | 2026-03-15T05:36:01.511886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899131 | REC_0015946 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 20 | 73 | female | 2 | 14 | 3.3 | 8 | sotorasib 960 mg daily | 11.3 | true | MSI-H | 2026-03-15T05:36:01.512369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499426 | REC_0015947 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 11.6 | 72 | female | 2 | 19 | 7 | 3 | osimertinib 80 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:36:01.512751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743679 | REC_0015948 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 3.9 | 79 | female | 1 | 73 | 2.7 | 8 | carboplatin + paclitaxel + pembrolizumab | 6.5 | false | MSS | 2026-03-15T05:36:01.513161+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476534 | REC_0015949 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 5.8 | 60 | male | 1 | 18 | 5.5 | 2 | pembrolizumab 200 mg q3w | 13.8 | true | MSS | 2026-03-15T05:36:01.513643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451779 | REC_0015950 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 12.7 | 79 | female | 1 | 18 | 4.8 | 2 | sotorasib 960 mg daily | 23.4 | false | MSI-H | 2026-03-15T05:36:01.515714+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322021 | REC_0015951 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 11.5 | 67 | female | 0 | 12 | 6.3 | 5 | osimertinib 80 mg daily | 8.9 | false | MSI-H | 2026-03-15T05:36:01.518138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709094 | REC_0015952 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 6.5 | 59 | female | 1 | 11 | 4.2 | 2 | sotorasib 960 mg daily | 24.7 | true | MSS | 2026-03-15T05:36:01.518842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_135528 | REC_0015953 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 11.9 | 52 | male | 0 | 27 | 3.1 | 2 | osimertinib 80 mg daily | 15.2 | true | MSS | 2026-03-15T05:36:01.521331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795717 | REC_0015954 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 14 | 66 | male | 1 | 22 | 3.5 | 1 | alectinib 600 mg BID | 24.7 | false | MSI-H | 2026-03-15T05:36:01.521862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200314 | REC_0015955 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 10.5 | 65 | male | 1 | 14 | 5 | 7 | entrectinib 600 mg daily | 15.8 | true | MSI-H | 2026-03-15T05:36:01.522308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878121 | REC_0015956 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 5 | 67 | female | 0 | 5 | 6 | 4 | pembrolizumab 200 mg q3w | 5.4 | false | MSS | 2026-03-15T05:36:01.522705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207268 | REC_0015957 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 7.2 | 66 | female | 0 | 21 | 8.4 | 6 | sotorasib 960 mg daily | 7.9 | false | MSS | 2026-03-15T05:36:01.523091+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729196 | REC_0015958 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.4 | 64 | female | 1 | 35 | 4.8 | 5 | pembrolizumab 200 mg q3w | 14.2 | false | MSS | 2026-03-15T05:36:01.523495+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584947 | REC_0015959 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 4 | 56 | female | 0 | 14 | 6.6 | 5 | osimertinib 80 mg daily | 15 | true | MSS | 2026-03-15T05:36:01.523872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_382403 | REC_0015960 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 8.8 | 77 | female | 2 | 22 | 4.9 | 8 | sotorasib 960 mg daily | 6 | false | MSS | 2026-03-15T05:36:01.524305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_126606 | REC_0015961 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 10.8 | 60 | male | 0 | 19 | 4.3 | 3 | alectinib 600 mg BID | 15 | true | MSI-H | 2026-03-15T05:36:01.524692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129622 | REC_0015962 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 11.5 | 64 | male | 0 | 14 | 3.5 | 2 | alectinib 600 mg BID | 9.8 | false | MSI-H | 2026-03-15T05:36:01.525078+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319186 | REC_0015963 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 7.8 | 73 | female | 2 | 30 | 9.3 | 6 | pembrolizumab 200 mg q3w | 5.8 | true | MSS | 2026-03-15T05:36:01.525472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501897 | REC_0015964 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 11.2 | 70 | female | 2 | 18 | 5.1 | 2 | sotorasib 960 mg daily | 16.3 | false | MSS | 2026-03-15T05:36:01.525875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202458 | REC_0015965 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 20.2 | 75 | female | 0 | 14 | 4.4 | 2 | alectinib 600 mg BID | 20.1 | true | MSS | 2026-03-15T05:36:01.527998+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739516 | REC_0015966 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 7.7 | 63 | female | 0 | 14 | 4 | 1 | pembrolizumab 200 mg q3w | 16 | false | MSS | 2026-03-15T05:36:01.528916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578888 | REC_0015967 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 7.2 | 55 | female | 0 | 17 | 7.6 | 7 | pembrolizumab 200 mg q3w | 13.2 | true | MSS | 2026-03-15T05:36:01.529423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419680 | REC_0015968 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 27 | 13.1 | 71 | female | 2 | 14 | 4.8 | 0 | sotorasib 960 mg daily | 35.5 | true | MSS | 2026-03-15T05:36:01.529912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254518 | REC_0015969 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 17.8 | 63 | male | 0 | 13 | 6.1 | 5 | entrectinib 600 mg daily | 12.7 | false | MSS | 2026-03-15T05:36:01.530348+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635976 | REC_0015970 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 11.8 | 67 | male | 1 | 18 | 7 | 5 | osimertinib 80 mg daily | 13.4 | true | MSS | 2026-03-15T05:36:01.530770+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705032 | REC_0015971 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 3.2 | 72 | female | 2 | 27 | 4.3 | 1 | osimertinib 80 mg daily | 21 | false | MSS | 2026-03-15T05:36:01.531140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_195317 | REC_0015972 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 5.6 | 73 | female | 0 | 19 | 7.3 | 2 | osimertinib 80 mg daily | 19.1 | true | MSS | 2026-03-15T05:36:01.531487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460478 | REC_0015973 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 17.1 | 48 | female | 0 | 15 | 6.5 | 1 | osimertinib 80 mg daily | 22 | false | MSS | 2026-03-15T05:36:01.531981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874096 | REC_0015974 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 7 | 70 | female | 1 | 7 | 8 | 4 | osimertinib 80 mg daily | 11.9 | false | MSS | 2026-03-15T05:36:01.532550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988603 | REC_0015975 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 3.2 | 67 | female | 0 | 26 | 6.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.8 | false | MSS | 2026-03-15T05:36:01.532930+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735250 | REC_0015976 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 14.9 | 64 | female | 0 | 24 | 5.3 | 6 | sotorasib 960 mg daily | 10.9 | false | MSS | 2026-03-15T05:36:01.533291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264558 | REC_0015977 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 9.5 | 85 | female | 2 | 14 | 6.4 | 1 | sotorasib 960 mg daily | 16 | true | MSS | 2026-03-15T05:36:01.533605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280953 | REC_0015978 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 10.8 | 76 | female | 1 | 23 | 4.3 | 2 | pembrolizumab 200 mg q3w | 14.7 | false | MSS | 2026-03-15T05:36:01.534103+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223572 | REC_0015979 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 11.1 | 73 | female | 2 | 21 | 5.5 | 3 | osimertinib 80 mg daily | 9.4 | false | MSS | 2026-03-15T05:36:01.534513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463241 | REC_0015980 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.4 | 64 | male | 1 | 41 | 6.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 14.2 | false | MSS | 2026-03-15T05:36:01.534865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961506 | REC_0015981 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 15.2 | 70 | female | 1 | 13 | 3.9 | 1 | alectinib 600 mg BID | 12.9 | true | MSS | 2026-03-15T05:36:01.535220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664826 | REC_0015982 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 10.7 | 57 | female | 1 | 21 | 3.8 | 2 | osimertinib 80 mg daily | 17.2 | false | MSS | 2026-03-15T05:36:01.535585+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487900 | REC_0015983 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 25 | 4.3 | 61 | female | 0 | 25 | 6.1 | 0 | carboplatin + paclitaxel + pembrolizumab | 29.2 | true | MSS | 2026-03-15T05:36:01.540999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956803 | REC_0015984 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 15.1 | 75 | female | 1 | 21 | 6.5 | 5 | osimertinib 80 mg daily | 7.8 | true | MSI-H | 2026-03-15T05:36:01.542132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437998 | REC_0015985 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 9 | 79 | female | 2 | 10 | 6.1 | 5 | osimertinib 80 mg daily | 16.2 | true | MSS | 2026-03-15T05:36:01.542992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103807 | REC_0015986 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6 | 63 | male | 1 | 73 | 5.9 | 3 | carboplatin + paclitaxel + pembrolizumab | 17.6 | true | MSS | 2026-03-15T05:36:01.543475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755734 | REC_0015987 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 24 | 14.1 | 66 | female | 1 | 9 | 4.5 | 0 | alectinib 600 mg BID | 43.9 | true | MSS | 2026-03-15T05:36:01.543843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839105 | REC_0015988 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 4.6 | 67 | female | 0 | 25 | 6 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.1 | true | MSS | 2026-03-15T05:36:01.544223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168773 | REC_0015989 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 13.6 | 60 | female | 0 | 9 | 4.6 | 5 | osimertinib 80 mg daily | 7.1 | false | MSS | 2026-03-15T05:36:01.544588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_935053 | REC_0015990 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 16.1 | 77 | female | 2 | 20 | 5.5 | 7 | sotorasib 960 mg daily | 9.7 | true | MSI-H | 2026-03-15T05:36:01.546336+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561121 | REC_0015991 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 15.3 | 64 | male | 1 | 11 | 6.5 | 6 | sotorasib 960 mg daily | 8.8 | true | MSS | 2026-03-15T05:36:01.547029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218270 | REC_0015992 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 15.1 | 67 | female | 0 | 16 | 5.3 | 4 | osimertinib 80 mg daily | 12.3 | false | MSI-H | 2026-03-15T05:36:01.547453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962147 | REC_0015993 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 4 | 70 | female | 2 | 6 | 5.6 | 9 | entrectinib 600 mg daily | 11.7 | true | MSS | 2026-03-15T05:36:01.548383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861993 | REC_0015994 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 13.4 | 61 | female | 1 | 28 | 5.5 | 7 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:36:01.549004+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502225 | REC_0015995 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 8.1 | 56 | male | 1 | 16 | 3.9 | 6 | alectinib 600 mg BID | 6 | true | MSS | 2026-03-15T05:36:01.549913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498264 | REC_0015996 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 7.4 | 73 | female | 0 | 5 | 5.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.8 | false | MSS | 2026-03-15T05:36:01.550403+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967920 | REC_0015997 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 10 | 90 | female | 2 | 21 | 4.2 | 1 | sotorasib 960 mg daily | 25 | false | MSI-H | 2026-03-15T05:36:01.550820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769834 | REC_0015998 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 7.8 | 74 | female | 1 | 26 | 5 | 8 | pembrolizumab 200 mg q3w | 12.2 | false | MSS | 2026-03-15T05:36:01.551281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_240407 | REC_0015999 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 11.7 | 66 | female | 0 | 11 | 4.2 | 5 | osimertinib 80 mg daily | 8.1 | false | MSI-H | 2026-03-15T05:36:01.551634+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183062 | REC_0016000 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 6.8 | 74 | male | 1 | 12 | 6.7 | 1 | osimertinib 80 mg daily | 9.9 | true | MSS | 2026-03-15T05:36:01.551960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.